{"id":"https://openalex.org/W2119792005","doi":"https://doi.org/10.1073/pnas.96.24.13989","title":"Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI\u03b1 subunit of protein kinase A after oral administration","display_name":"Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI\u03b1 subunit of protein kinase A after oral administration","alternate_titles":[],"publication_year":1999,"publication_date":"1999-11-23","ids":{"openalex":"https://openalex.org/W2119792005","doi":"https://doi.org/10.1073/pnas.96.24.13989","mag":"2119792005","pmid":"https://pubmed.ncbi.nlm.nih.gov/10570186","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/24178"},"language":"en","primary_location":{"id":"doi:10.1073/pnas.96.24.13989","doi":"https://doi.org/10.1073/pnas.96.24.13989","is_oa":false,"landing_page_url":"https://doi.org/10.1073/pnas.96.24.13989","pdf_url":null,"source":{"id":"https://openalex.org/S125754415","display_name":"Proceedings of the National Academy of Sciences","issn_l":"0027-8424","issn":["0027-8424","1091-6490"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320052","host_organization_name":"National Academy of Sciences","host_organization_lineage":["https://openalex.org/P4310320052"],"host_organization_lineage_names":["National Academy of Sciences"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2119792005"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC24178/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072171083","display_name":"Hui Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hui Wang","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005513706","display_name":"Qiuyin Cai","orcid":"https://orcid.org/0000-0002-9384-5648","observed_orcids":["https://orcid.org/0000-0002-9384-5648"]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Qiuyin Cai","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103109800","display_name":"Xiaofei Zeng","orcid":"https://orcid.org/0000-0001-9857-2848","observed_orcids":["https://orcid.org/0000-0001-9857-2848"]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiaofei Zeng","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101416140","display_name":"Dong Su Yu","orcid":"https://orcid.org/0000-0001-6089-4905","observed_orcids":["https://orcid.org/0000-0001-6089-4905"]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dong Yu","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069014764","display_name":"Sudhir Agrawal","orcid":"https://orcid.org/0000-0003-4275-2510","observed_orcids":["https://orcid.org/0000-0003-4275-2510"]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sudhir Agrawal","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088978867","display_name":"Ruiwen Zhang","orcid":"https://orcid.org/0000-0001-5323-0772","observed_orcids":["https://orcid.org/0000-0001-5323-0772","https://orcid.org/0009-0005-1146-9474"]},"institutions":[{"id":"https://openalex.org/I17301866","display_name":"University of Alabama","ror":"https://ror.org/03xrrjk67","country_code":"US","type":"education","lineage":["https://openalex.org/I17301866"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Ruiwen Zhang","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, and Comprehensive Cancer Center, University of Alabama, Birmingham, AL 35294-0019; and Hybridon, Inc., 155 Fortune Boulevard, Milford, MA 01757","institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5088978867"],"corresponding_institution_ids":["https://openalex.org/I17301866","https://openalex.org/I32389192","https://openalex.org/I4390039250"],"apc_list":null,"apc_paid":null,"fwci":3.1603,"has_fulltext":false,"cited_by_count":136,"citation_normalized_percentile":{"value":0.92753077,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"96","issue":"24","first_page":"13989","last_page":"13994"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.7407000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.7407000064849854,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10432","display_name":"DNA and Nucleic Acid Chemistry","score":0.16200000047683716,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9340000152587891},{"id":"https://openalex.org/keywords/protein-kinase-a","display_name":"protein kinase A","score":0.8849999904632568},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8510000109672546},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.859000027179718},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.996999979019165},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.800000011920929},{"id":"https://openalex.org/keywords/cisplatin-combination-therapy","display_name":"cisplatin combination therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.75},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/leukemia","display_name":"leukemia","score":0.8460000157356262},{"id":"https://openalex.org/keywords/tumor-accumulation","display_name":"tumor accumulation","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C129312508","wikidata":"https://www.wikidata.org/wiki/Q133686","display_name":"Oligonucleotide","level":3,"score":0.7611221075057983},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5610424280166626},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5457872152328491},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5388277769088745},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5238081216812134},{"id":"https://openalex.org/C104292427","wikidata":"https://www.wikidata.org/wiki/Q899781","display_name":"Protein subunit","level":3,"score":0.44751501083374023},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.42871659994125366},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4037335216999054},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3706092834472656},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.32962220907211304},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.30432748794555664},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.27474039793014526},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1975744664669037},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12300282716751099},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.06914222240447998},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016376","descriptor_name":"Oligonucleotides, Antisense","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017868","descriptor_name":"Cyclic AMP-Dependent Protein Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D017868","descriptor_name":"Cyclic AMP-Dependent Protein Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D018922","descriptor_name":"HL-60 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054756","descriptor_name":"Cyclic AMP-Dependent Protein Kinase RIalpha Subunit","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1073/pnas.96.24.13989","doi":"https://doi.org/10.1073/pnas.96.24.13989","is_oa":false,"landing_page_url":"https://doi.org/10.1073/pnas.96.24.13989","pdf_url":null,"source":{"id":"https://openalex.org/S125754415","display_name":"Proceedings of the National Academy of Sciences","issn_l":"0027-8424","issn":["0027-8424","1091-6490"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320052","host_organization_name":"National Academy of Sciences","host_organization_lineage":["https://openalex.org/P4310320052"],"host_organization_lineage_names":["National Academy of Sciences"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:24178","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC24178/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proc Natl Acad Sci U S A","raw_type":"Text"},{"id":"pmid:10570186","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10570186","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proceedings of the National Academy of Sciences of the United States of America","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:24178","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC24178/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Proc Natl Acad Sci U S A","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2780072328","display_name":"MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY","funder_award_id":"R01CA080698","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":51,"referenced_works":["https://openalex.org/W37675134","https://openalex.org/W1199216903","https://openalex.org/W1240040893","https://openalex.org/W1602739278","https://openalex.org/W1616035683","https://openalex.org/W1906809867","https://openalex.org/W1921475843","https://openalex.org/W1969617808","https://openalex.org/W1972985481","https://openalex.org/W1977083658","https://openalex.org/W1992905023","https://openalex.org/W1994489381","https://openalex.org/W1997460670","https://openalex.org/W1997976112","https://openalex.org/W2003367624","https://openalex.org/W2009366889","https://openalex.org/W2009593695","https://openalex.org/W2011684562","https://openalex.org/W2022406699","https://openalex.org/W2026050954","https://openalex.org/W2029158611","https://openalex.org/W2030505446","https://openalex.org/W2037233457","https://openalex.org/W2046160436","https://openalex.org/W2047366876","https://openalex.org/W2048812496","https://openalex.org/W2049502625","https://openalex.org/W2051323583","https://openalex.org/W2052973382","https://openalex.org/W2060606238","https://openalex.org/W2063818810","https://openalex.org/W2064563978","https://openalex.org/W2065949421","https://openalex.org/W2067401769","https://openalex.org/W2078024480","https://openalex.org/W2079804110","https://openalex.org/W2088348110","https://openalex.org/W2088900497","https://openalex.org/W2094809928","https://openalex.org/W2113121371","https://openalex.org/W2124721652","https://openalex.org/W2125255467","https://openalex.org/W2145888569","https://openalex.org/W2182207230","https://openalex.org/W2240703322","https://openalex.org/W2275740247","https://openalex.org/W2325127218","https://openalex.org/W2417607928","https://openalex.org/W4236425814","https://openalex.org/W4250596474","https://openalex.org/W4298289936"],"related_works":["https://openalex.org/W2065220084","https://openalex.org/W1989402937","https://openalex.org/W1588936614","https://openalex.org/W2439577188","https://openalex.org/W2416869371","https://openalex.org/W2147153171","https://openalex.org/W2064563978","https://openalex.org/W2154842546","https://openalex.org/W2414289348","https://openalex.org/W2324487827"],"abstract_inverted_index":{"Overexpression":[0],"of":[1,5,30,57,60,103,106,117,144,150,161,176,185],"the":[2,31,55,87,107,129,137,145,162,177,182],"RIalpha":[3,183],"subunit":[4,184],"cAMP-dependent":[6],"protein":[7],"kinase":[8],"(PKA)":[9],"has":[10,18],"been":[11,19],"demonstrated":[12],"in":[13,76,90,94,134,164,197],"various":[14],"human":[15,48,61,104],"cancers.":[16],"PKA":[17,186],"suggested":[20],"as":[21,43,189],"a":[22,44,77,84,171,190],"potential":[23],"target":[24],"for":[25,173],"cancer":[26,49,63,69,74,138,191],"therapy.":[27],"The":[28,51,115,142],"goal":[29],"present":[32],"study":[33,168],"was":[34,132],"to":[35,47,181],"evaluate":[36],"an":[37,157],"anti-PKA":[38],"antisense":[39,130,178],"oligonucleotide":[40,53,88,131,146,152,163,179],"(mixed-backbone":[41],"oligonucleotide)":[42],"therapeutic":[45,192],"approach":[46],"treatment.":[50],"identified":[52],"inhibited":[54],"growth":[56],"cell":[58],"lines":[59],"colon":[62,108],"(LS174T,":[64],"DLD-1),":[65],"leukemia":[66],"(HL-60),":[67],"breast":[68,110],"(MCF-7,":[70],"MDA-MB-468),":[71],"and":[72,80,98,112,122,159],"lung":[73,113],"(A549)":[75],"time-,":[78],"concentration-,":[79],"sequence-dependent":[81],"manner.":[82],"In":[83],"dose-dependent":[85],"manner,":[86],"displayed":[89],"vivo":[91],"antitumor":[92],"activity":[93],"severe":[95],"combined":[96],"immunodeficient":[97],"nude":[99],"mice":[100,155],"bearing":[101],"xenografts":[102],"cancers":[105],"(LS174T),":[109],"(MDA-MB-468),":[111],"(A549).":[114],"routes":[116],"drug":[118],"administration":[119,149],"were":[120,126],"intraperitoneal":[121],"oral.":[123],"Synergistic":[124],"effects":[125],"found":[127],"when":[128],"used":[133,194],"combination":[135,198],"with":[136,199],"chemotherapeutic":[139],"agent":[140,193],"cisplatin.":[141],"pharmacokinetics":[143],"after":[147],"oral":[148],"(35)S-labeled":[151],"into":[153],"tumor-bearing":[154],"indicated":[156],"accumulation":[158],"retention":[160],"tumor":[165],"tissue.":[166],"This":[167],"further":[169],"provides":[170],"basis":[172],"clinical":[174],"studies":[175],"targeted":[180],"(GEM":[187],"231)":[188],"alone":[195],"or":[196],"conventional":[200],"chemotherapy.":[201]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2119792005","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
